Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate. Article
Full Text via DOI: 10.1200/JCO.2021.39.15_suppl.4109
Web of Science: 000708120602209